Zdrowie i gospodarka · 14/01/2013

FDA Releases Draft Guidance on Abuse-Deterrent Opioids Evaluation and Labeling

The Food and Drug Administration (FDA) has made available a draft guidance for industry outlining how to study and evaluate the abuse-deterrent properties of opioid analgesic products, as well as what claims can be included in their labeling, in an effort to combat opioid abuse.